A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA

There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections...

Full description

Saved in:
Bibliographic Details
Main Authors: Lubna Jahanzeb (Author), Zahida Memon (Author), M. Owais Ismail (Author)
Format: Book
Published: ziauddin University, 2019-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2ac48a6037d84d97a647a9219e1e4d3f
042 |a dc 
100 1 0 |a Lubna Jahanzeb  |e author 
700 1 0 |a Zahida Memon  |e author 
700 1 0 |a M. Owais Ismail  |e author 
245 0 0 |a A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA 
260 |b ziauddin University,   |c 2019-04-01T00:00:00Z. 
500 |a 2313-7371 
500 |a 2308-2593 
520 |a There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections. It has become difficult to treat P.aeruginosa infections in current scenario as antimicrobial resistance has increased against antimicrobial drugs. So it has become a challenge to select optimal antibacterial drug or regimen for the patient treatment to prevent further resistance. Ceftolozane/tazobactam (C/T) is a novel combination of broad spectrum antibacterial agents that is 5th generation cephalosporin antibiotic and β-lactamase inhibitor. It is considered a best choice for the treatment of complicated infections including ventilator-associated bacterial pneumonia, nosocomial pneumonia, urinary tract infections and intra-abdominal infections. Ceftolozane/tazobactam possess sensitivity of about >90% against β-lactam resistant strains of P.aeruginosa. This combination is superior to various other antibiotics and antibacterial regimen so it has initiated a new chapter in an era of complicated infections. This review appraises the comparison of different broad spectrum antibiotics like levofloxacin, meropenem and tobramycin and antibacterial combinations including tazobactam/cefepime, ceftazidime/avibactam, tazobactam/piperacillin, with the Ceftolozane/tazobactam combination. This article also evaluates the effect of C/T if given in combination with other drugs like daptomycin, metronidazole and amikacin. 
546 |a EN 
690 |a Critical infections 
690 |a Multi drug resistant, P.aeruginosa 
690 |a Ceftolozane/tazobactam 
690 |a Biochemistry 
690 |a QD415-436 
690 |a Dentistry 
690 |a RK1-715 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Medicine (General) 
690 |a R5-920 
655 7 |a article  |2 local 
786 0 |n Pakistan Journal of Medicine and Dentistry, Vol 7, Iss 2 (2019) 
787 0 |n https://ojs.zu.edu.pk/pjmd/article/view/180 
787 0 |n https://doaj.org/toc/2313-7371 
787 0 |n https://doaj.org/toc/2308-2593 
856 4 1 |u https://doaj.org/article/2ac48a6037d84d97a647a9219e1e4d3f  |z Connect to this object online.